Verona Pharma

$8.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.16 (-1.91%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Verona Pharma and other stocks, options, and ETFs commission-free!

About VRNA

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound.

CEO
David S. Zaccardelli
Employees
27
Headquarters
London, Greater London
Founded
2005
Market Cap
490.64M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
90.02K
High Today
$8.42
Low Today
$8.06
Open Price
$8.42
Volume
16.86K
52 Week High
$15.71
52 Week Low
$3.70

VRNA Earnings

-$1.09
-$0.73
-$0.36
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected Apr 29, Pre-Market

You May Also Like

DLR-J
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure